Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 2/1997

01-11-1997 | ORIGINAL ARTICLE

Influence of exposure and infusion times on the cytotoxicity and pharmacokinetics of cis - malonato[(4R, 5R )-4,5-bis(aminomethyl)- 2-isopropyl-1,3-dioxolane]platinum(II)

Authors: Hun-Taek Kim, D.-K. Kim, Yong-Baik Cho, Taek-Soo Kim, I. Jung, Key H. Kim, Dae Seog Heo, Yung-Jue Bang, Sang-Goo Shin, Noe Kyeong Kim

Published in: Cancer Chemotherapy and Pharmacology | Issue 2/1997

Login to get access
Metadata
Title
Influence of exposure and infusion times on the cytotoxicity and pharmacokinetics of cis - malonato[(4R, 5R )-4,5-bis(aminomethyl)- 2-isopropyl-1,3-dioxolane]platinum(II)
Authors
Hun-Taek Kim
D.-K. Kim
Yong-Baik Cho
Taek-Soo Kim
I. Jung
Key H. Kim
Dae Seog Heo
Yung-Jue Bang
Sang-Goo Shin
Noe Kyeong Kim
Publication date
01-11-1997
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 2/1997
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s002800050716

Other articles of this Issue 2/1997

Cancer Chemotherapy and Pharmacology 2/1997 Go to the issue

ORIGINAL ARTICLE

Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin

ORIGINAL ARTICLE

Population pharmacokinetics of total and unbound etoposide

ORIGINAL ARTICLE

Toxicity, pharmacokinetics, and in vitro hemodialysis clearance of ifosfamide and metabolites in an anephric pediatric patient with Wilms' tumor

ORIGINAL ARTICLE

Pharmacokinetics of CPT-11 in rhesus monkeys

SHORT COMMUNICATION

Initial clinical trial and pharmacokinetics of ThymitaqTM (AG337) by 10-day continuous infusion in patients with advanced solid tumors

ORIGINAL ARTICLE

All-trans-retinoic acid modulation of drug-metabolizing enzyme activities: investigation with selective metabolic drug probes
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits